Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%GlobeNewsWire • 10/08/19
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?Zacks Investment Research • 09/26/19
With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To CommercializationSeeking Alpha • 09/25/19
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)GlobeNewsWire • 09/16/19
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/10/19
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/26/19
Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/19
Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/18/19